trending Market Intelligence /marketintelligence/en/news-insights/trending/di4pxy6uv-wodk-3tk-7fq2 content esgSubNav
In This List

Regulus Therapeutics director to retire

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Regulus Therapeutics director to retire

Regulus Therapeutics Inc. said director Mark Foletta will retire from the board upon the expiration of his current term ending at the 2018 annual meeting of stockholders.

The San Diego, Calif.-based company said Foletta's decision was a result of his concurrent service as the executive vice president and CFO for cancer drug developer Tocagen Inc.